Zacks Investment Research Lowers Bionomics (OTCMKTS:BNOEF) to Hold

Zacks Investment Research downgraded shares of Bionomics (OTCMKTS:BNOEF) from a buy rating to a hold rating in a report published on Wednesday morning, Zacks.com reports.

According to Zacks, “Bionomics Limited is a biopharmaceutical company. It discovers and develops drug for the treatment of central nervous system disorders and cancer. The companys product pipeline includes BNC210, a novel and proprietary negative allosteric modulator, which is in Phase II clinical trials; BNC375, a small molecule therapeutics for the treatment of cognitive impairment in alzheimers’s disease; BNC101, a monoclonal antibody that targets cancer stem cells and BNC105, a novel compound to disrupt the blood vessels. It operates primarily in Australia, France and the United States. Bionomics Limited is based in Thebarton, Australia. “

Separately, HC Wainwright restated a buy rating on shares of ACASTI PHARM-TS in a research report on Wednesday, June 26th.



BNOEF stock opened at $0.01 on Wednesday. The firm has a 50 day moving average of $0.04. Bionomics has a 1 year low of $0.01 and a 1 year high of $0.70.

Bionomics Company Profile

Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancer in Australia, France, and the United States. It operates through Drug Discovery and Development, and Contract Services segments.

Recommended Story: Quick Ratio

Get a free copy of the Zacks research report on Bionomics (BNOEF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.